Please enable JavaScript to continue using this application.

Compare $FATE vs $TLSI | Chartloom

Compare

$FATE vs $TLSI

Fate Therapeutics Inc · TriSalus Life Sciences Inc

FATE

Fate Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Compare $FATE vs $TLSI

Comparing Fate Therapeutics Inc and TriSalus Life Sciences Inc

FATEFate Therapeutics Inc

TLSITriSalus Life Sciences Inc

FATEFate Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

54.34x

Rev growth (TTM)

-23.4%

YTD performance

120.2%

52W performance

44.4%

FCF yield

-41.6%

TLSITriSalus Life Sciences Inc

Market cap

$249M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.61x

Rev growth (TTM)

25.2%

YTD performance

-33.4%

52W performance

-16.3%

FCF yield

-9.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FATE

TLSI

Detailed metrics comparison

FATE

Fate Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Market Cap

FATE$254M

TLSI$249M

Enterprise Value

FATE$234M

TLSI$236M

Price

FATE$2.18

TLSI$4.06

P/E Ratio

FATEN/A

TLSIN/A

P/S Ratio

FATE39.15x

TLSI5.53x

EV/Sales

FATE35.98x

TLSI5.24x

EV/EBITDA

FATE0.00x

TLSI0.00x

P/B Ratio

FATE1.81x

TLSI40.61x

P/FCF Ratio

FATEN/A

TLSIN/A

EV/FCF

FATE-2.21x

TLSI-10.14x

PEG Ratio

FATEN/A

TLSIN/A

Forward P/E (NTM)

FATEN/A

TLSIN/A

Forward P/S (NTM)

FATE54.34x

TLSI3.61x

Revenue (TTM)

FATE$6M

TLSI$45M

Revenue Growth (YoY)

FATE-23.4%

TLSI25.2%

Forward Rev Growth

FATE-17.6%

TLSI40.1%

Gross Margin (TTM)

FATE0.0%

TLSI85.8%

Operating Margin (TTM)

FATE0.0%

TLSI0.0%

EBITDA Margin (TTM)

FATE-1873.4%

TLSI-66.4%

Net Margin (TTM)

FATE-1941.1%

TLSI-130.2%

FCF Margin (TTM)

FATE-1627.8%

TLSI-51.6%

Net Income (TTM)

FATE$-126M

TLSI$-59M

FCF (TTM)

FATE$-106M

TLSI$-23M

EPS (TTM)

FATE-$1.05

TLSI-$1.01

ROE (TTM)

FATE-6508.0%

TLSI-7902.0%

ROA (TTM)

FATE-4173.0%

TLSI-5499.0%

ROIC (TTM)

FATE-6174.0%

TLSI-1789.0%

Cash

FATE$32M

TLSI$46M

Debt

FATE$12M

TLSI$33M

Net Cash/Debt

FATE$21M

TLSI$13M

Current Ratio (TTM)

FATE4.85x

TLSI5.35x

Quick Ratio (TTM)

FATE4.74x

TLSI4.72x

Debt/Equity (TTM)

FATE0.08x

TLSI5.05x

Debt/Assets (TTM)

FATE0.0%

TLSI0.0%

Interest Coverage (TTM)

FATEN/A

TLSIN/A

Net Debt/EBITDA (TTM)

FATE0.00x

TLSI0.00x

Beta

FATE2.67

TLSI0.46

52W Performance

FATE44.4%

TLSI-16.3%

YTD Performance

FATE120.2%

TLSI-33.4%

% from 52W High

FATE-32.5%

TLSI-48.9%

% from 52W Low

FATE129.5%

TLSI84.5%

Asset Turnover (TTM)

FATE0.02x

TLSI0.88x

FCF Yield (TTM)

FATE-41.6%

TLSI-9.3%

Earnings Yield (TTM)

FATE-49.6%

TLSI-23.5%

Dividend Yield (TTM)

FATEN/A

TLSIN/A

Rule of 40

FATE-1,651.1

TLSI-26.4

EV/GP/RG

FATEN/A

TLSI0.11

Ticker research

View FATE research View TLSI research

Metric	FATE Fate Therapeutics Inc	TLSI TriSalus Life Sciences Inc
Market & Valuation
Market Cap	$254M	$249M
Enterprise Value	$234M	$236M
Price	$2.18	$4.06
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	5.53x
EV/Sales	35.98x	5.24x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	40.61x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-10.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	3.61x
Revenue & Growth
Revenue (TTM)	$6M	$45M
Revenue Growth (YoY)	-23.4%	25.2%
Forward Rev Growth	-17.6%	40.1%
Profitability
Gross Margin (TTM)	0.0%	85.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	-66.4%
Net Margin (TTM)	-1941.1%	-130.2%
FCF Margin (TTM)	-1627.8%	-51.6%
Net Income (TTM)	$-126M	$-59M
FCF (TTM)	$-106M	$-23M
EPS (TTM)	-$1.05	-$1.01
ROE (TTM)	-6508.0%	-7902.0%
ROA (TTM)	-4173.0%	-5499.0%
ROIC (TTM)	-6174.0%	-1789.0%
Financial Health
Cash	$32M	$46M
Debt	$12M	$33M
Net Cash/Debt	$21M	$13M
Current Ratio (TTM)	4.85x	5.35x
Quick Ratio (TTM)	4.74x	4.72x
Debt/Equity (TTM)	0.08x	5.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	0.46
52W Performance	44.4%	-16.3%
YTD Performance	120.2%	-33.4%
% from 52W High	-32.5%	-48.9%
% from 52W Low	129.5%	84.5%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.88x
FCF Yield (TTM)	-41.6%	-9.3%
Earnings Yield (TTM)	-49.6%	-23.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	-26.4
EV/GP/RG	N/A	0.11
Ticker research	View FATE research	View TLSI research

Valuation

P/S Ratio

TLSI

5.53x

FATE

39.15x

EV/FCF

TLSI

-10.14x

FATE

-2.21x

Growth & revenue

Revenue Growth TTM

TLSI

25.2%

FATE

-23.4%

Forward Revenue Growth

TLSI

40.1%

FATE

-17.6%

Profitability & performance

Gross Margin

TLSI

85.8%

FATE

0.0%

ROE

FATE

-6508.0%

TLSI

-7902.0%

FCF Yield %

TLSI

-9.3%

FATE

-41.6%

52-Week Performance

FATE

44.4%

TLSI

-16.3%

Detailed metrics comparison

FATE

Fate Therapeutics Inc

TLSI

TriSalus Life Sciences Inc

Market Cap

FATE$254M

TLSI$249M

Enterprise Value

FATE$234M

TLSI$236M

Price

FATE$2.18

TLSI$4.06

P/E Ratio

FATEN/A

TLSIN/A

P/S Ratio

FATE39.15x

TLSI5.53x

EV/Sales

FATE35.98x

TLSI5.24x

EV/EBITDA

FATE0.00x

TLSI0.00x

P/B Ratio

FATE1.81x

TLSI40.61x

P/FCF Ratio

FATEN/A

TLSIN/A

EV/FCF

FATE-2.21x

TLSI-10.14x

PEG Ratio

FATEN/A

TLSIN/A

Forward P/E (NTM)

FATEN/A

TLSIN/A

Forward P/S (NTM)

FATE54.34x

TLSI3.61x

Revenue (TTM)

FATE$6M

TLSI$45M

Revenue Growth (YoY)

FATE-23.4%

TLSI25.2%

Forward Rev Growth

FATE-17.6%

TLSI40.1%

Gross Margin (TTM)

FATE0.0%

TLSI85.8%

Operating Margin (TTM)

FATE0.0%

TLSI0.0%

EBITDA Margin (TTM)

FATE-1873.4%

TLSI-66.4%

Net Margin (TTM)

FATE-1941.1%

TLSI-130.2%

FCF Margin (TTM)

FATE-1627.8%

TLSI-51.6%

Net Income (TTM)

FATE$-126M

TLSI$-59M

FCF (TTM)

FATE$-106M

TLSI$-23M

EPS (TTM)

FATE-$1.05

TLSI-$1.01

ROE (TTM)

FATE-6508.0%

TLSI-7902.0%

ROA (TTM)

FATE-4173.0%

TLSI-5499.0%

ROIC (TTM)

FATE-6174.0%

TLSI-1789.0%

Cash

FATE$32M

TLSI$46M

Debt

FATE$12M

TLSI$33M

Net Cash/Debt

FATE$21M

TLSI$13M

Current Ratio (TTM)

FATE4.85x

TLSI5.35x

Quick Ratio (TTM)

FATE4.74x

TLSI4.72x

Debt/Equity (TTM)

FATE0.08x

TLSI5.05x

Debt/Assets (TTM)

FATE0.0%

TLSI0.0%

Interest Coverage (TTM)

FATEN/A

TLSIN/A

Net Debt/EBITDA (TTM)

FATE0.00x

TLSI0.00x

Beta

FATE2.67

TLSI0.46

52W Performance

FATE44.4%

TLSI-16.3%

YTD Performance

FATE120.2%

TLSI-33.4%

% from 52W High

FATE-32.5%

TLSI-48.9%

% from 52W Low

FATE129.5%

TLSI84.5%

Asset Turnover (TTM)

FATE0.02x

TLSI0.88x

FCF Yield (TTM)

FATE-41.6%

TLSI-9.3%

Earnings Yield (TTM)

FATE-49.6%

TLSI-23.5%

Dividend Yield (TTM)

FATEN/A

TLSIN/A

Rule of 40

FATE-1,651.1

TLSI-26.4

EV/GP/RG

FATEN/A

TLSI0.11

Ticker research

View FATE research View TLSI research

Metric	FATE Fate Therapeutics Inc	TLSI TriSalus Life Sciences Inc
Market & Valuation
Market Cap	$254M	$249M
Enterprise Value	$234M	$236M
Price	$2.18	$4.06
P/E Ratio	N/A	N/A
P/S Ratio	39.15x	5.53x
EV/Sales	35.98x	5.24x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.81x	40.61x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.21x	-10.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	54.34x	3.61x
Revenue & Growth
Revenue (TTM)	$6M	$45M
Revenue Growth (YoY)	-23.4%	25.2%
Forward Rev Growth	-17.6%	40.1%
Profitability
Gross Margin (TTM)	0.0%	85.8%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-1873.4%	-66.4%
Net Margin (TTM)	-1941.1%	-130.2%
FCF Margin (TTM)	-1627.8%	-51.6%
Net Income (TTM)	$-126M	$-59M
FCF (TTM)	$-106M	$-23M
EPS (TTM)	-$1.05	-$1.01
ROE (TTM)	-6508.0%	-7902.0%
ROA (TTM)	-4173.0%	-5499.0%
ROIC (TTM)	-6174.0%	-1789.0%
Financial Health
Cash	$32M	$46M
Debt	$12M	$33M
Net Cash/Debt	$21M	$13M
Current Ratio (TTM)	4.85x	5.35x
Quick Ratio (TTM)	4.74x	4.72x
Debt/Equity (TTM)	0.08x	5.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.67	0.46
52W Performance	44.4%	-16.3%
YTD Performance	120.2%	-33.4%
% from 52W High	-32.5%	-48.9%
% from 52W Low	129.5%	84.5%
Efficiency & Yields
Asset Turnover (TTM)	0.02x	0.88x
FCF Yield (TTM)	-41.6%	-9.3%
Earnings Yield (TTM)	-49.6%	-23.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,651.1	-26.4
EV/GP/RG	N/A	0.11
Ticker research	View FATE research	View TLSI research